Noteworthy Tuesday Option Activity: AVGO, CVS, V

Unusually large options volumes traded in CVS and Visa today: CVS saw 30,530 contracts (~3.1M underlying shares), about 47.1% of its one‑month average daily volume (6.5M), led by 13,847 contracts in the $83 call expiring Jan 23, 2026 (~1.4M shares). Visa recorded 32,727 contracts (~3.3M shares), ~44.7% of its one‑month average daily volume (7.3M), with 7,225 contracts in the $340 Jan 23, 2026 call (~722.5k shares). The concentrated call activity indicates notable bullish/options positioning that could influence near‑term flow and gamma-driven price dynamics in both stocks.

Analysis

Market structure: Concentrated, long-dated call buys in CVS and V (Jan 2026 $83 and $340 strikes) imply large directional demand or structured-product placement rather than retail one-offs. Dealers who sold calls will delta-hedge by buying stock as underlying rises, creating a self-reinforcing bid in the near term; size is meaningful (calls represent ~45–47% of ADV -> ~3M shares), so expect measurable order-flow impact over days–weeks. Competitive impact: for CVS this flow can temporarily support share price vs. smaller peers; for V it reinforces leaderboard positioning in payments but won’t change fundamental fees or merchant economics.

Risk assessment: Tail risks include regulatory action on pharmacy margins (CVS) or payments regulation / large-scale fraud (V) and macro-driven transaction declines if consumer spending drops >5% YoY; these would blow up long-dated call value. Time horizons matter: immediate (0–14 days) delta-hedge buying, short-term (weeks–months) IV repricing and possible mean reversion, long-term (to Jan 2026) fundamentals and macro cycles dominate. Hidden dependency: trades may be part of structured notes (long calls + short bonds), so expiration flow could be neutral or reverse when dealer unwind occurs. Key catalysts: quarterly earnings, Fed rate moves (30–90 days), and any healthcare/payments regulation in next 6–12 months.

Trade implications: Prefer option-defined risk exposure rather than outright stock exposure. For CVS, buy-call spreads to cap premium decay; for V, exploit skew by buying long-dated call spreads or selling short-dated premium into elevated IV. Size trades to 1–3% of portfolio each, use stops at 20% adverse move or IV spike above 40% vs baseline. Sector rotation: slight overweight to defensive healthcare MCap names only if you accept long-dated optionality cost.

Contrarian angles: The market may be misreading concentrated call volume as pure bullish conviction — it can be protective positioning or yield structure. Reaction could be overdone: dealer hedging can push prices up short-term and then unwind into stagnation, producing negative theta for call buyers; historical parallels include large OTM call blocks in 2019–2021 that produced transient squeezes but mixed long-term returns. Unintended consequence: a buy-side unwind at quarter boundaries (90–120 days) could create sharp reversals; plan exit windows around earnings and quarter-ends.

Key Decisions for Investors

• Establish a capped-risk bullish position in CVS via Jan 2026 $83/$95 call spreads sized to 1.5% of portfolio notional (buy $83, sell $95). Exit if spread value falls by 50% or if CVS declines >20% from entry within 90 days.
• Establish a long Visa position via Jan 2026 $340/$420 call spread sized to 1–2% notional; take profits if V > $420 or if IV rises >30% from trade entry, cut losses at 20% adverse move.
• If willing to own stock, sell 30–60 day OTM puts on CVS at strikes 5–8% below spot to collect premium (limit to 1% portfolio exposure) — assign only if comfortable owning at that discount; close if implied vol jumps >25%.
• Implement pair/flow hedge: offset 50% of option directional exposure by shorting equivalent delta in sector ETF (XLV for CVS exposure, or a 0.5x notional short on large-cap financials for V) to neutralize short-term dealer-hedge squeezes; unwind into confirmed earnings beats or 60–120 day windows.